このアイテムのアクセス数: 0

このアイテムのファイル:
このアイテムは一定期間後に公開されます。
公開日については,アイテム画面の「著作権等」でご確認ください。
タイトル: Initial PSA 100 ng/ml 以上の非転移性前立腺癌に対する局所治療の有用性の検討 : 多施設共同後ろ向き研究
その他のタイトル: Availability of Local Therapy to Castration-Resistant Prostate Cancer for M0 Patients with Initial Prostate Specific Antigen 100 ng/ml or Higher
著者: 黒本, 暁人  KAKEN_name
田中, 峻希  KAKEN_name
小山, 淳太朗  KAKEN_name
後藤, 拓郎  KAKEN_name
木村, 信吾  KAKEN_name
勝又, 有記  KAKEN_name
明円, 真吾  KAKEN_name
小澤, 迪喜  KAKEN_name
諸角, 謙人  KAKEN_name
佐藤, 真彦  KAKEN_name
星, 宣次  KAKEN_name
沼畑, 健司  KAKEN_name
荒井, 陽一  KAKEN_name
著者名の別形: Kuromoto, Akito
Tanaka, Takaki
Koyama, Juntaro
Goto, Takuro
Kimura, Shingo
Katsumata, Yuki
Myoen, Shingo
Ozawa, Michinobu
Morozumi, Kento
Sato, Masahiko
Hoshi, Senji
Numahata, Kenji
Arai, Yoichi
キーワード: Prostate cancer
No metastases
PSA 100 ng/ml, Local therapy
Androgen deprivation therapy
発行日: 31-Dec-2017
出版者: 泌尿器科紀要刊行会
誌名: 泌尿器科紀要 = Acta urologica Japonica
巻: 63
号: 12
開始ページ: 515
終了ページ: 520
抄録: Prostate cancer patients with initial PSA 100 ng/ml or greater who received transrectal ultrasoundguided prostate biopsy and were staged as M0 by imaging studies from 2011 to 2014 in seven hospitals, were enrolled in the study. Castration-resistant prostate cancer (CRPC)-free survival was compared between the two treatment groups : androgen deprivation therapy (ADT) alone and ADT plus local therapy. Of 142 prostate cancer patients with initial PSA 100 ng/ml or greater, 49 (34.5%) had no metastases and final analysis was performed on 46 patients. Thirty one M0 patients received ADT alone, and 15 received ADT plus local therapy. During follow-up (median 31 months, range 1-56 months) 13 patients (42%) in the ADT alone group progressed to CRPC. One- and two-year CRPC-free survival rates were 72.5 and 53%, respectively. No patients with ADT plus local therapy developed CRPC, and time to CRPC was prolonged significantly (p=0.002). On multivariate analysis for the group with ADT alone, PSA nadir of more than 0. 2 ng/ml and cN1 were independent predictors for progression to CRPC (p=0.009, 0.031). About one third of prostate cancer patients with initial PSA 100 ng/ml or greater had clinically no metastases. Local therapy to prostate combined with ADT may prolong time to CRPC compared with ADT alone. A subset of men with a PSA nadir of more than 0.2 ng/ml after ADT and cN1 could benefit from local therapy.
著作権等: 許諾条件により本文は2019/01/01に公開
DOI: 10.14989/ActaUrolJap_63_12_515
URI: http://hdl.handle.net/2433/228962
PubMed ID: 29370662
出現コレクション:Vol.63 No.12

アイテムの詳細レコードを表示する

Export to RefWorks


出力フォーマット 


このリポジトリに保管されているアイテムはすべて著作権により保護されています。